

Ghady Haidar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7484705/ghady-haidar-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50
papers

1,708
citations

19
h-index

41
g-index

59
ext. papers

2,518
ext. citations

7.9
avg, IF

5.62
L-index

#	Paper	IF	Citations
50	Daptomycin-Resistant Bacteremia Is Associated With Prior Daptomycin Use and Increased Mortality After Liver Transplantation.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofab659	1	0
49	Fever of Unknown Origin.. <i>New England Journal of Medicine</i> , 2022 , 386, 463-477	59.2	4
48	896. Examining the Impact of the COVID-19 Pandemic on Delivery of HIV Care and Prevention Services Among Patients in a Ryan White Clinic. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S539-S539	1	
47	Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21days.. <i>Contemporary Clinical Trials</i> , 2021 , 113, 106652	2.3	1
46	Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. <i>Clinical Infectious Diseases</i> , 2021 , 73, e4090-e4099	11.6	159
45	Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. <i>Science</i> , 2021 , 371, 1139-1142	33.3	264
44	Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients 2021 ,		44
43	Circulating microbial cell-free DNA is associated with inflammatory host-responses in severe pneumonia. <i>Thorax</i> , 2021 , 76, 1231-1235	7.3	1
42	Susceptibility of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	9
41	The UPMC OPTIMISE-C19 (OPTimizing Treatment and Impact of Monoclonal antibodies through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization. <i>Trials</i> , 2021 , 22, 363	2.8	7
40	Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1397-e1401	11.6	17
39	Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab254	1	31
38	Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab353	1	30
37	Preprocedural SARS-CoV-2 Testing to Sustain Medically Needed Health Care Delivery During the COVID-19 Pandemic: A Prospective Observational Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab022	1.2	4
36	Invasive Fungal Infections after Anti-CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy: State of the Evidence and Future Directions. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	5
35	SARS-CoV-2 Viremia is Associated with COVID-19 Severity and Predicts Clinical Outcomes. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	20
34	Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.. <i>Journal of Clinical Virology Plus</i> , 2021 , 1, 100026		0

33	The Evolving Challenge of Infections in Cirrhosis. <i>New England Journal of Medicine</i> , 2021 , 385, 1150-1151	59.2	1
32	Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. <i>Clinical Infectious Diseases</i> , 2021 , 73, e815-e821	11.6	52
31	202. The Impact and Safety of Discontinuing Routine Surveillance Blood Culture Monitoring in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S209-S209 [†]		
30	Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties. <i>Current Opinion in Infectious Diseases</i> , 2020 , 33, 449-457	5.4	8
29	Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence. <i>Journal of Infectious Diseases</i> , 2020 , 221, S23-S31	7	28
28	Reply to Lewis and Kontoyiannis. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1803-1804	11.6	1
27	555. Effectiveness of a Treatment Team on Adherence to Health System Guidelines for Hydroxychloroquine Use During Two Phases of the COVID-19 Epidemic. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S343-S343	1	
26	1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S583-S583	1	1
25	Clarifying the HOPE Act landscape: The challenge of donors with false-positive HIV results. <i>American Journal of Transplantation</i> , 2020 , 20, 617-619	8.7	9
24	Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis. <i>Clinical Infectious Diseases</i> , 2020 , 71, 672-676	11.6	32
23	Brief Report: Willingness to Accept HIV-Infected and Increased Infectious Risk Donor Organs Among Transplant Candidates Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, 88-92	3.1	7
22	Intra-abdominal infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019 , 33, e13595	3.8	17
21	sp: An emerging infection amongst chronic granulomatous disease patients. A case of disseminated infection by a putatively novel species complex involving the heart. <i>Medical Mycology Case Reports</i> , 2019 , 24, 54-57	1.7	10
20	A case of immune reconstitution syndrome complicating progressive multifocal leukoencephalopathy after kidney transplant: Clinical, pathological, and radiographic features. <i>Transplant Infectious Disease</i> , 2019 , 21, e13162	2.7	4
19	Successful lung transplantation from a hepatitis C RNA-positive donor to a hepatitis C treatment-experienced recipient with cystic fibrosis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019 , 158, e155-e157	1.5	4
18	Heart or lung transplant outcomes in HIV-infected recipients. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 1296-1305	5.8	20
17	245. Plasma and Respiratory Specimen Metagenomic Sequencing for the Diagnosis of Severe Pneumonia in Mechanically-Ventilated Patients. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S138-S138	1	1
16	How We Approach Combination Antifungal Therapy for Invasive Aspergillosis and Mucormycosis in Transplant Recipients. <i>Transplantation</i> , 2018 , 102, 1815-1823	1.8	5

15	Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa. <i>Journal of Clinical Microbiology</i> , 2018 , 56,	9.7	32
14	2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant Pseudomonas aeruginosa (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S729-S729	1	1
13	Mutations in That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	114
12	Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	86
11	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. <i>Clinical Infectious Diseases</i> , 2017 , 65, 110-120	11.6	167
10	The Times, They are a-Changing: HOPE for HIV-to-HIV Organ Transplantation. <i>Transplantation</i> , 2017 , 101, 1987-1995	1.8	10
9	Viral infections in solid organ transplant recipients: novel updates and a review of the classics. <i>Current Opinion in Infectious Diseases</i> , 2017 , 30, 579-588	5.4	41
8	Phellinus species: An emerging cause of refractory fungal infections in patients with X-linked chronic granulomatous disease. <i>Mycoses</i> , 2017 , 60, 155-160	5.2	19
7	Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S297-S297	7	78
6	Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1615-1618	11.6	285
5	Invasive Tracheobronchial Aspergillosis in a Lung Transplant Recipient Receiving Belatacept as Salvage Maintenance Immunosuppression: A Case Report. <i>Transplantation Proceedings</i> , 2016 , 48, 275-8	1.1	9
4	Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum- β Lactamase-Producing Enterobacter Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5200-11	5.9	34
3	: Shedding New Light on an Inveterate Yeast. <i>Journal of Fungi (Basel, Switzerland)</i> , 2015 , 1, 115-129	5.6	7
2	Diagnostic Modalities for Invasive Mould Infections among Hematopoietic Stem Cell Transplant and Solid Organ Recipients: Performance Characteristics and Practical Roles in the Clinic. <i>Journal of Fungi (Basel, Switzerland)</i> , 2015 , 1, 252-276	5.6	4
1	Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis		6